Member access

4-Traders Homepage  >  Shares  >  Copenhagen Stock Exchange  >  Novo Nordisk A/S    NOVO.B   DK0060534915

NOVO NORDISK A/S (NOVO.B)

164
SummaryChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Develops, manufactures, markets and distributes pharmaceutical products

Novo Nordisk AS is engaged in the development, manufacture, and marketing of pharmaceutical products.

It operates through the Diabetes Care and Biopharmaceuticals segments.

The Diabetes Care segment deals with the research, development, manufacture, and marketing of products within the areas of insulin, glucagon-like-peptide 1 and related delivery systems, oral anti-diabetic products, and obesity.

The Biopharmaceuticals segment handles the research, development, manufacture, and distribution of products within the areas of haemophilia, growth hormone, hormone replacement, inflammation and other therapy areas.

The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Number of employees : 37 978 persons.
Sales per Businesses
20122013Delta
DKK (in Million)%DKK (in Million)%
Diabetes Care60,88778%65,45678.3% +6.98%
Biopharmaceuticals17,13922%18,11621.7% +5.39%
Corporate/Unallocated-----
Managers
NameAgeSinceTitle
Göran A. Ando, MD652005Chairman
Anne Marie Handrup Kverneland582000Director
Henrik Gürtler612005Director
Lars Rebien Sørensen601982Chief Executive Officer
Jesper Brandgaard, MBA512000Chief Financial Officer & Executive Vice President
Mike Rulis--Vice President-Corporate Communications
Stig Strøbæk501998Director
Hannu Ryöppönen622009Independent Director
Ulrik Joakim Hjulmand-Lassen522010Director
Lise Kingo531988Chief of Staff & Executive Vice President
Shareholders
Sector
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Pharmaceuticals - NEC
Advertisement
Surperformance© rating
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
PER
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
More Ratings
Sector Pharmaceuticals
Growth (Revenue) Profitability
JOHNSON & JOHNSON
NOVARTIS AG
ROCHE HOLDING LTD..
PFIZER INC.
MERCK & CO., INC.
SANOFI
GLAXOSMITHKLINE P..
BAYER AG
NOVO NORDISK A/S
BRISTOL-MYERS SQU..
ELI LILLY AND CO
ABBOTT LABORATORI..
ACTAVIS PLC
TEVA PHARMACEUTIC..
ALLERGAN, INC.
SHIRE PLC
VALEANT PHARMACEU..
TAKEDA PHARMACEUT..
REGENERON PHARMAC..
CSL LIMITED
Sector Pharmaceuticals
Company contact information
Novo Nordisk A/S
Novo Allé
Bagsværd 2880

Phone : +45.44.44.88.88
Fax : +45.44.49.05.55
Web : www.novonordisk.com
© 2014 Factset   
Dynamic quotes  
ON
| OFF